EUVIMEDEUVIMED entdecken
Multizentrische Studie

Effect of Initial eGFR and Albuminuria Changes on Clinical Outcomes in People With Diabetes Receiving SGLT2 Inhibitors

Birdie Huang, Yi-Wei Kao, Kun-Chi Yen, Shao-Wei Chen iD, Tze-Fan Chao iD, Yi-Hsin Chan iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf133 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Birdie Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Cardiovascular Department, Chang Gung Memorial Hospital, Taoyuan 333423, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Albuminuria, Glomerular Filtration Rate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan, Chang Gung Memorial Hospital, Linkou, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The relationship between initial changes in estimated glomerular filtration rate (eGFR) and urine albumin to creatinine ratio (UACR), and their independent association with clinical outcomes in type 2 diabetes (T2D) patients receiving sodium-glucose cotransporter 2 inhibitors (SGLT2is), remains unclear.

Objective

This study aimed to investigate the association between initial changes in eGFR and UACR with consequent cardiovascular and kidney outcomes in an Asian population with T2D following SGLT2i treatment in a real-world setting.

Methods

Using a large multicenter medical database in Taiwan, we analyzed 8222 T2D patients with baseline and 3-month follow-up eGFR and UACR measurements, receiving SGLT2is between June 1, 2016, and December 31, 2021. We assessed risks of major adverse renal events (MARE), major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and all-cause mortality using a Cox proportional hazards model.

Results

After 3 months of SGLT2i treatment, patients were categorized based on early changes in eGFR (no decline, 0%-10% decline, > 10% decline) and UACR (no reduction, 0%-30% reduction, > 30% reduction). Among those with no initial eGFR decline (40.9%), 19.8% had no initial UACR reduction, 8.4% had 0% to 30% reduction, and 12.7% had greater than 30% reduction. For those with greater than 10% initial eGFR decline (21.5%), 6.5% had no UACR reduction, 4.3% had 0% to 30% reduction, and 10.7% had greater than 30% reduction. Patients with greater than 10% initial eGFR decline but no UACR reduction showed higher risks of MARE (adjusted HR [aHR]: 2.34; 95% CI, 1.32-4.15), MACE (aHR: 1.83; 95% CI, 1.01-3.29), and HHF/cardiovascular death (aHR: 1.93; 95% CI, 1.05-3.55) compared to those with modest early eGFR decline and UACR reduction.

Conclusion

T2D patients experiencing profound early eGFR decline without concordant UACR reduction while on SGLT2is represent a high-risk subgroup with worse clinical outcomes. These findings suggest the need for closer monitoring and potentially more aggressive therapeutic strategies for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2AlbuminuriaGlomerular Filtration RateDiabetic NephropathiesHumansFemaleMaleMiddle AgedAgedTaiwanCardiovascular DiseasesFollow-Up StudiesTreatment OutcomePrognosisRetrospective Studies

Stichwörter der Autor:innen

estimated glomerular filtration ratesodium-glucose cotransporter-2 inhibitortype 2 diabetes mellitusurine albumin-to-creatinine ratio

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • The Cardiovascular Department, Chang Gung Memorial Hospital, Taoyuan 333423, Taiwan.
  • Department of Applied Statistics and Information Science, Ming Chuan University, Taoyuan City 333321, Taiwan.
  • Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei 242062, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
  • Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan City 333423, Taiwan.
  • Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Taoyuan 333423, Taiwan.

ORCID-Profile: Shao-Wei Chen, Tze-Fan Chao, Yi-Hsin Chan

Förderung

  • Ministry of Science and Technology, Taiwan
  • Chang Gung Memorial Hospital, Linkou, Taiwan

Zitieren

APA

Huang, B., Kao, Y. W., Yen, K. C., Chen, S. W., Chao, T. F., & Chan, Y. H. (2025). Effect of Initial eGFR and Albuminuria Changes on Clinical Outcomes in People With Diabetes Receiving SGLT2 Inhibitors. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf133

Vancouver

Huang B, Kao YW, Yen KC, Chen SW, Chao TF, Chan YH. Effect of Initial eGFR and Albuminuria Changes on Clinical Outcomes in People With Diabetes Receiving SGLT2 Inhibitors. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf133

BibTeX
@article{Huang2025,
  author = {Huang, Birdie and Kao, Yi-Wei and Yen, Kun-Chi and Chen, Shao-Wei and Chao, Tze-Fan and Chan, Yi-Hsin},
  title = {Effect of Initial eGFR and Albuminuria Changes on Clinical Outcomes in People With Diabetes Receiving SGLT2 Inhibitors},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf133}
}
Kostenlos starten →